Accès gratuit
Numéro
Med Sci (Paris)
Volume 21, Numéro 6-7, Juin–Juillet 2005
Page(s) 669 - 670
Section Derniére Heure
DOI https://doi.org/10.1051/medsci/2005216-7669
Publié en ligne 15 juin 2005
  1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) : classification of myeloid neoplasms. Blood 2002; 100 : 2292–302.
  2. Wong S, Witte ON. The BCR-ABL story : bench to bedside and back. Annu Rev Immunol 2004; 22 : 247–306.
  3. Cross NC, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 2002; 16 : 1207–12.
  4. Gotlib J, Cools J, Malone JM, et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia implications for diagnosis, classification and management. Blood 2004; 103 : 2879–91.
  5. Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 2004; 104 : 1931–9.
  6. Wadleigh M, De Angelo DJ, Griffin JD, Stone RM. After chronic myelogenous leukemia : tyrosine kinase inhibitors in others malignancies. Blood 2005; 105 : 22–30.
  7. Pahl HL. Towards a molecular understanding of polycythemia rubra vera. Eur J Biochem 2000; 267: 3395–401.
  8. Spivak JL. Polycythemia vera : myths, mechanisms, and management. Blood 2002; 100 : 4272–90.
  9. Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004; 32 : 179–87.
  10. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434 : 1144–8.
  11. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002; 30 : 229–36.
  12. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365 : 1054–61.
  13. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352 : 1779–90.
  14. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7 : 387–97.
  15. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in Polycythemia vera. J Biol Chem 2005 online.
  16. Goldman JM. A unifying mutation in chronic myeloproliferative disorders. N Engl J Med 2005; 352 : 1744–6.
  17. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders : it all makes sense. Blood 2005; 105 : 4187–90.
  18. Shannon K, Van Etten RA. JAKing up hematopoietic proliferation. Cancer Cell 2005; 7 : 291–3.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.